Evidence map›Paper›PMID 27934883›Full record

ArticleCancer gene therapy2017

Preclinical evaluation of radiation and systemic, RGD-targeted, adeno-associated virus phage-TNF gene therapy in a mouse model of spontaneously metastatic melanoma.

T J Quinn, N Healy, A Sara, E Maggi, C S Claros, R Kabarriti, L Scandiuzzi, L Liu, J Gorecka, A Adem and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

T J QuinnDepartment of Radiation Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
N HealyDepartment of Radiation Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
A SaraDepartment of Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
E MaggiDepartment of Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
C S ClarosDepartment of Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
R KabarritiDepartment of Radiation Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
L ScandiuzziDepartment of Radiation Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
L LiuDepartment of Radiation Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
J GoreckaDepartment of Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
A AdemDepartment of Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
I BasuDepartment of Radiation Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Z YuanDepartment of Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
C GuhaDepartment of Radiation Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of melanoma in the United States continues to rise, with metastatic lesions notoriously recalcitrant to therapy. There are limited effective treatment options available and a great need for more effective therapies that can be rapidly integrated in the clinic. In this study, we demonstrate that the combination of RGD-targeted adeno-associated virus phage (RGD-AAVP-TNF) with hypofractionated radiation therapy results in synergistic inhibition of primary syngeneic B16 melanoma in a C57 mouse model. Furthermore, this combination appeared to modify the tumor microenvironment, resulting in decreased Tregs in the draining LN and increased tumor-associated macrophages within the primary tumor. Finally, there appeared to be a reduction in metastatic potential and a prolongation of overall survival in the combined treatment group. These results indicate the use of targeted TNF gene therapy vector with radiation treatment could be a valuable treatment option for patients with metastatic melanoma.

Indexed as

AnimalsCell Line, TumorCombined Modality TherapyDependovirusDisease Models, AnimalDrug Evaluation, PreclinicalFemaleGenetic TherapyGenetic VectorsMelanomaMelanoma, ExperimentalMiceNeoplasm MetastasisNeovascularization, PathologicOligopeptidesRadiotherapyarginyl-glycyl-aspartic acidOligopeptidesTumor Necrosis Factor-alpha

Identifiers

PMID27934883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.